AMH predicts live-birth chances in women with diminished ovarian reserve
MedWire News: Researchers have identified a cutoff value for anti-Müllerian hormone (AMH) that effectively identifies, independent of age, the likelihood of a live birth in women with diminished ovarian reserve (DOR).
The findings are of importance, as "patients with severe DOR may still demonstrate reasonable pregnancy […] but unacceptably low live-birth rates due to high pregnancy wastage," say Norbert Gleicher (Center for Human Reproduction, New York, USA) and co-authors.
The researchers measured AMH levels in 295 women with DOR, of whom 174 had an AMH ≤1.05 ng/ml. Logistic regression was performed with live birth as the dependent variable and AMH ≤ or >1.05 ng/ml, while adjusting for age, months in treatment, diagnosis, and race.
Live-birth rates were significantly different from clinical pregnancy rates, mainly due to higher miscarriage rates at AMH levels of 0.41-1.05 ng/ml. All AMH categories below 1.05 ng/ml were associated with similarly low live-birth rates.
Women with AMH >1.05 ng/ml were 4.6-fold more likely to have a live birth than those with AMH ≤1.05 ng/ml. Women with AMH ≤1.05 ng/ml were significantly older (39.2 vs 35.2 years), had higher follicle stimulating hormone levels (20.2 vs 10.8 mIU/ml), higher body mass index (25.7 vs 23.6 kg/m2), and more DOR at admission diagnosis (58.6 vs 29.8 percent) compared with those who had AMH >1.05 ng/ml.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2011
By Ingrid Grasmo